0001171843-21-004277.txt : 20210611 0001171843-21-004277.hdr.sgml : 20210611 20210611060516 ACCESSION NUMBER: 0001171843-21-004277 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210611 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210611 DATE AS OF CHANGE: 20210611 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 211009901 BUSINESS ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 181 OYSTER POINT BLVD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 f8k_061121.htm FORM 8-K Form 8-K
0001629137 False 0001629137 2021-06-11 2021-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  June 11, 2021

_______________________________

Global Blood Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware001-3753927-4825712
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

181 Oyster Point Blvd.

South San Francisco, California 94080

(Address of Principal Executive Offices) (Zip Code)

(650) 741-7700

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareGBTThe NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 8.01. Other Events.

On June 11, 2021, Global Blood Therapeutics, Inc. issued a press release titled "New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description
   
99.1 Press Release dated June 11, 2021
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Global Blood Therapeutics, Inc.
   
  
Date: June 11, 2021By: /s/ Jeffrey Farrow        
  Jeffrey Farrow
  Chief Financial Officer
(Principal Financial Officer)
  

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress

Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation

Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the Phase 3 HOPE Study

SOUTH SAN FRANCISCO, Calif., June 11, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced new data from the Phase 2a HOPE-KIDS 1 Study that showed children with sickle cell disease (SCD) ages 4 to 11 years treated with Oxbryta® (voxelotor) tablets experienced significant improvements in hemoglobin levels. These data, along with results from two real-world evidence studies of Oxbryta, will be presented at the European Hematology Association (EHA) 2021 Virtual Congress, taking place online June 9-17, 2021.

“The encouraging results seen with Oxbryta treatment in younger patients living with sickle cell disease support our belief that Oxbryta can have a positive impact across a wide age range of people living with this devastating, lifelong disease by reducing the sickling and destruction of red blood cells, thereby improving anemia and hemolysis – hallmarks of the condition,” said Ted W. Love, M.D., president and chief executive officer of GBT. “Additionally, we are pleased by the growing body of real-world evidence demonstrating the meaningful benefits of Oxbryta in patients ages 12 and older. Collectively, these data reinforce our commitment to seek broad access for patients and add to our confidence in the potential of this innovative medicine to address the urgent needs of sickle cell disease patients in the U.S., Europe, the Middle East and beyond.”

New Data Analysis from Phase 2a HOPE-KIDS 1 Study (Oral Abstract #S260)
A new analysis of data from 45 children with SCD ages 4 to 11 years enrolled in the open-label Phase 2a HOPE-KIDS 1 Study (GBT440-007) showed that treatment with Oxbryta (1,500 mg or weight-based equivalent dispersed in a pediatric-appropriate formulation) resulted in rapid and sustained improvements in hemoglobin. An increase in hemoglobin of greater than 1 g/dL from baseline was observed in 47% of patients as early as two weeks and sustained through 24 weeks, consistent with results in patients ages 12 years and older in the Phase 3 HOPE Study. Concurrent improvements in markers of hemolysis were also observed.

“The potentially life-threatening complications of sickle cell disease are the cumulative result of damage caused by the sickling and destruction of red blood cells that begins at a very young age. While the goal is to treat sickle cell disease early in life to prevent potential long-term consequences, current therapeutic options for younger patients are limited and do not adequately address the underlying cause of this devastating disease,” said Clark Brown, M.D., Ph.D., director of sickle cell clinical research at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta, a primary investigator of the study. “With consistent results to published data in adults, the data from the HOPE-KIDS 1 Study underscore the potential for Oxbryta to provide important benefits in children as young as 4 years old, with a favorable safety profile.”

The findings support the equivalency of weight-based dosing in children ages 4 to 11 years and the 1,500 mg dose of Oxbryta in adolescents ages 12 to 17 years. The mean hemoglobin occupancy was 26% in children ages 4 to 11, which is consistent with results in the Phase 3 HOPE Study. In the HOPE-KIDS 1 study, Oxbryta was well tolerated and no new adverse safety signals were detected. The most commonly reported treatment-related adverse events were transient and self-limiting (diarrhea (11%), vomiting (11%) and rash (11%)).

Real-World Experience with Oxbryta
Findings from two new analyses of real-world experience with Oxbryta demonstrated improvements in hemoglobin consistent with results observed in the Phase 3 HOPE Study, which were previously published in The New England Journal of Medicine.

  • An analysis of real-world outcomes in 77 patients with SCD treated in a single-center case series (Abstract #EP1209) showed that hemoglobin levels increased by an average of 2 g/dL after treatment with Oxbryta along with corresponding improvements in markers of hemolysis. A hemoglobin response greater than 1 g/dL with Oxbryta was observed in 62% of patients without the use of hydroxyurea and 87% of patients treated with hydroxyurea and Oxbryta.

    The robust hematologic response was associated with improved clinical status, as measured by the Clinical Global Impression of Change (CGI-C) and Patient Global Impression of Change (PGI-C) scales, validated outcomes measures that provide holistic assessments of the effect of treatment by the physicians and patients, respectively. Few adverse events were recorded, and all were resolved with dose modification. The safety profile observed in this analysis was consistent with the approved label for Oxbryta.
  • A separate study (Abstract #EP1206) provides a study design overview of RETRO, GBT’s multicenter retrospective data collection and analysis registry, which will collect real-world outcomes in up to 300 adults and adolescents with SCD treated with Oxbryta at 10 sites across the United States. The study will incorporate medical records for each patient one year before and up to one year after starting Oxbryta and will capture clinical outcome measures, health resource utilization data, and laboratory measures. An initial analysis of outcomes in 20 patients enrolled in the RETRO study at a single study site was reported. After 12 months of treatment with Oxbryta, 50% of patients had increased hemoglobin greater than 1 g/dL.

Patient registration and data collection in the RETRO Study is ongoing. GBT also recently initiated the prospective PROSPECT Study, which is designed to enroll up to 750 patients at approximately 25 U.S. sites. GBT intends to collect data from these registries to enable deeper understanding of the long-term efficacy and safety of Oxbryta.

About Sickle Cell Disease
Sickle cell disease (SCD) affects an estimated 100,000 people in the United States,1 an estimated 52,000 people in Europe,2 and millions of people throughout the world, particularly among those whose ancestors are from sub-Saharan Africa.1 It also affects people of Hispanic, South Asian, Southern European and Middle Eastern ancestry.1 SCD is a lifelong inherited rare blood disorder that impacts hemoglobin, a protein carried by red blood cells that delivers oxygen to tissues and organs throughout the body.3 Due to a genetic mutation, individuals with SCD form abnormal hemoglobin known as sickle hemoglobin. Through a process called hemoglobin polymerization, red blood cells become sickled – deoxygenated, crescent-shaped and rigid.3-5 The sickling process causes hemolytic anemia (low hemoglobin due to red blood cell destruction) and blockages in capillaries and small blood vessels, which impede the flow of blood and oxygen throughout the body. The diminished oxygen delivery to tissues and organs can lead to life-threatening complications, including stroke and irreversible organ damage.4-7

About Oxbryta® (voxelotor) tablets
Oxbryta (voxelotor) is an oral, once-daily therapy for patients with sickle cell disease (SCD). Oxbryta works by increasing hemoglobin’s affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, Oxbryta inhibits sickle hemoglobin polymerization and the resultant sickling and destruction of red blood cells, which are primary pathologies faced by every single person living with SCD. Through addressing hemolytic anemia and improving oxygen delivery throughout the body, GBT believes that Oxbryta has the potential to modify the course of SCD. On Nov. 25, 2019, Oxbryta received U.S. Food and Drug Administration (FDA) accelerated approval for the treatment of SCD in adults and children 12 years of age and older.8

As a condition of accelerated approval, GBT will continue to study Oxbryta in the HOPE-KIDS 2 Study, a post-approval confirmatory study using transcranial Doppler (TCD) flow velocity to assess the ability of the therapy to decrease stroke risk in children 2 to 15 years of age.

In recognition of the critical need for new SCD treatments, the FDA granted Oxbryta Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations for the treatment of patients with SCD. Additionally, Oxbryta has been granted Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), and the European Commission (EC) has designated Oxbryta as an orphan medicinal product for the treatment of patients with SCD. 

The EMA has accepted for review GBT’s Marketing Authorization Application (MAA) seeking full marketing authorization of Oxbryta in Europe to treat hemolytic anemia in SCD patients ages 12 years and older. GBT also plans to seek regulatory approval to expand the potential use of Oxbryta in the United States for the treatment of SCD in children as young as 4 years old.

Important Safety Information
Oxbryta should not be taken if the patient has had an allergic reaction to voxelotor or any of the ingredients in Oxbryta. See the end of the patient leaflet for a list of the ingredients in Oxbryta. Oxbryta can cause serious side effects, including serious allergic reactions. Patients should tell their health care provider or get emergency medical help right away if they get rash, hives, shortness of breath or swelling of the face.

Patients receiving exchange transfusions should talk to their health care provider about possible difficulties with the interpretation of certain blood tests when taking Oxbryta.

The most common side effects of Oxbryta include headache, diarrhea, stomach (abdominal) pain, nausea, tiredness, rash and fever. These are not all the possible side effects of Oxbryta.

Before taking Oxbryta, patients should tell their health care provider about all medical conditions, including if they have liver problems; if they are pregnant or plan to become pregnant as it is not known if Oxbryta can harm an unborn baby; or if they are breastfeeding or plan to breastfeed as it is not known if Oxbryta can pass into breastmilk or if it can harm a baby. Patients should not breastfeed during treatment with Oxbryta and for at least two weeks after the last dose.

Patients should tell their health care provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Some medicines may affect how Oxbryta works. Oxbryta may also affect how other medicines work.

Patients are advised to call their doctor for medical advice about side effects. Side effects can be reported to the FDA at 1-800-FDA-1088. Side effects can also be reported to Global Blood Therapeutics at 1-833-428-4968 (1-833-GBT-4YOU).

Full Prescribing Information for Oxbryta is available at Oxbryta.com.

About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next-generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including statements containing the words “will,” “anticipates,” “plans,” “believes,” “forecast,” “estimates,” “expects” and “intends,” or similar expressions. These forward-looking statements are based on GBT’s current expectations and actual results could differ materially. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. GBT intends these forward-looking statements, including statements regarding GBT’s priorities, dedication, commitment, focus, goals, mission and vision; safety, efficacy and mechanism of action of Oxbryta and other product characteristics; significance of reducing sickling and hemolysis and raising hemoglobin; commercialization, delivery, availability, use and commercial and medical potential of Oxbryta; GBT’s commitment to seek broad patient access to Oxbryta; significance of data to be presented at the EHA Congress, including support for the use of Oxbryta and manner of dosing in children; ongoing and planned studies and related protocols, activities and expectations; regulatory submissions, review and approval to potentially expand the approved use of Oxbryta for more patients in the U.S. and to treat patients in Europe and other territories; altering the treatment, course and care of SCD and mitigating related complications; potential and advancement of GBT’s pipeline, including inclacumab and other product candidates; and working on new targets and discovering, developing and delivering treatments, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and GBT makes this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect GBT’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. GBT can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond GBT’s control, including, without limitation, risks and uncertainties relating to the COVID-19 pandemic, including the extent and duration of the impact on GBT’s business, including commercialization activities, regulatory efforts, research and development, corporate development activities and operating results, which will depend on future developments that are highly uncertain and cannot be accurately predicted, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease; the risks that GBT is continuing to establish its commercialization capabilities and may not be able to successfully commercialize Oxbryta; risks associated with GBT’s dependence on third parties for development, manufacture, distribution and commercialization activities related to Oxbryta; government and third-party payer actions, including those relating to reimbursement and pricing; risks and uncertainties relating to competitive products and other changes that may limit demand for Oxbryta; the risks regulatory authorities may require additional studies or data to support continued commercialization of Oxbryta; the risks that drug-related adverse events may be observed during commercialization or clinical development; data and results may not meet regulatory requirements or otherwise be sufficient for further development, regulatory review or approval; compliance with obligations under the Pharmakon loan; and the timing and progress of activities under GBT’s collaborations and license agreements; along with those risks set forth in GBT’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and in GBT’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors in GBT’s subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, GBT assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

References

  1. Centers for Disease Control and Prevention website. Sickle Cell Disease (SCD). https://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed June 3, 2019.
  2. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182125. Accessed June 12, 2020.
  3. National Heart, Lung, and Blood Institute website. Sickle Cell Disease. https://www.nhlbi.nih.gov/health-topics/sickle-cell-disease. Accessed August 5, 2019.
  4. Rees DC, et al. Lancet. 2010;376(9757):2018-2031.
  5. Kato GJ, et al. Nat Rev Dis Primers. 2018;4:18010.
  6. Kato GJ, et al. J Clin Invest. 2017;127(3):750-760. 
  7. Caboot JB, et al. Paediatr Respir Rev. 2014;15(1):17-23.
  8. Oxbryta (voxelotor) tablets prescribing information. South San Francisco, Calif. Global Blood Therapeutics, Inc.; November 2019.

Contact:
Steven Immergut (media)
650.410.3258
simmergut@gbt.com

Courtney Roberts (investors)
650.351.7881
croberts@gbt.com

 EX-101.SCH 3 gnw-20190101.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gnw-20190101_def.xml XBRL DEFINITION FILE EX-101.LAB 5 gnw-20190101_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Class A [Member] Preferred Class A [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gnw-20190101_pre.xml XBRL PRESENTATION FILE XML 7 f8k_061121_htm.xml IDEA: XBRL DOCUMENT 0001629137 2021-06-11 2021-06-11 iso4217:USD shares iso4217:USD shares 0001629137 false 8-K 2021-06-11 Global Blood Therapeutics, Inc. DE 001-37539 27-4825712 181 Oyster Point Blvd. South San Francisco CA 94080 650 741-7700 false false false false Common Stock, par value $0.001 per share GBT NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover
Jun. 11, 2021
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 11, 2021
Entity File Number 001-37539
Entity Registrant Name Global Blood Therapeutics, Inc.
Entity Central Index Key 0001629137
Entity Tax Identification Number 27-4825712
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 181 Oyster Point Blvd.
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 741-7700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol GBT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://globenewswire.com/role/Cover Cover Cover 1 false false All Reports Book All Reports f8k_061121.htm exh_991.htm gnw-20190101.xsd gnw-20190101_def.xml gnw-20190101_lab.xml gnw-20190101_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f8k_061121.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "gnw-20190101_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "f8k_061121.htm" ] }, "labelLink": { "local": [ "gnw-20190101_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "gnw-20190101_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "gnw-20190101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 63, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gnw", "nsuri": "http://globenewswire.com/20190101", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_061121.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://globenewswire.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "f8k_061121.htm", "contextRef": "Form8K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Class A [Member]" } } }, "localname": "PreferredClassAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://globenewswire.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } ZIP 15 0001171843-21-004277-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-21-004277-xbrl.zip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�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end